SILIRUM
Inactivated vaccine for cattle against bovine paratuberculosis cause by Mycobacterium avium spp. paratuberculosis
Lifetime protection with just one dose
One dose of Silirum produces a lasting cell response and lifelong immunological memory.
Control bovine paratuberculosis at any stage of the animal’s life
Silirum can be used to vaccinate both young and adult animals. If the prevalence of the disease is high in the herd, it is best to vaccinate all the animals.
Increased productivity in vaccinated herds
The benefits of vaccination in cattle not only include lower mortality rates and degrees of infection, it also prevents future decreased yield compared to infected livestock.
01
Reduces bacterial load
Silirum vaccination reduces the MAP load.
02
Vaccination with Silirum significantly reduces the MAP load.
03
By reducing MAP shedding in feces, it decreases environmental contamination and the spread of the disease.
04
It can be used in animals at any stage of their life.
05
Vaccination of sheep and goats is the most effective strategy to prevent paratuberculosis, financially speaking.
06
By reducing the bacterial load in the intestines, it decreases the number and severity of lesions caused by bacteria.
07
With the resulting decrease in replacement rate.
08
Dr. Ramon A. Juste, PhD in Veterinary Medicine and president of the International Association for Paratuberculosis, explains the benefits of paratuberculosis vaccination in animals.
- Facciuolo, A., Lee, A.H., Trimble, M.J., Rawlyk, N., Townsend, H.G.G., Bains, M., Arsic, N., Mutharia, L.M., Potter, A., Gerdts, V., Napper, S., Hancock, R.E.W. & Griebel, P.J. (2020) A Bovine Enteric Mycobacterium Infection Model to Analyze Parenteral Vaccine-Induced Mucosal Immunity and Accelerate Vaccine Discovery. Frontiers in Immunology. 11:586659. doi: 10.3389/fimmu.2020.586659.
- Juste, R.A., Geijo M.V., Elguezaba,l N., Sevilla, I.A., Alonso-Hearn, M. & Garrido, J.M. (2021) Paratuberculosis vaccination specific and non-specific effects on cattle lifespan. Vaccine. 12;39(11):1631-1641. doi: 10.1016/j.vaccine.2021.01.058.
